Legal
Filter News
Found 9,755 articles
-
CytoDyn has spent the past two years under siege. In an exclusive interview, Cyrus Arman, president, told BioSpace how the company is looking to turn the page.
-
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
3/14/2023
Mindset Pharma Inc. today announced that the Company has been made aware that Reunion Neuroscience Inc. (“Reunion”) has filed a lawsuit against Mindset in the United States District Court for the District of New Jersey asserting, among others, inventorship and co-ownership of one of Mindset’s patents, inequitable conduct, and breach of contract.
-
Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics
3/3/2023
Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties.
-
Senate Bill 1162, a law requiring employers to include pay ranges in all job advertisements, went into effect in California January 1. Here's how employers are responding.
-
Xlear Provides New Data to the Dept. Of Justice; Study Showing Nasal Spray Reduces COVID-19 Infections by 62% Included
2/27/2023
Xlear has supplemented the numerous scientific studies it has already provided the Department of Justice and the Federal Trade Commission (FTC) in the government’s lawsuit against Xlear.
-
The Pregnant Workers Fairness Act (PWFA) has been praised by many in the life sciences who see it as a step forward in protecting the rights of pregnant employees.
-
Trade secrets litigations and disputes have been on the rise in recent years, and given the FTC's recent proposal to ban all non-compete agreements nationwide, the trend is likely to continue.
-
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against GimotiStipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed
1/30/2023
Evoke Pharma, Inc. today announced that a joint stipulation of dismissal has been filed in the GIMOTI ® patent infringement case (Civil Action No. 1:22-cv-02019) in the United States District Court for the District of New Jersey.
-
Sen. Elizabeth Warren (D-MA) voiced concerns to the FTC regarding the prospective acquisitions of Horizon Pharmaceuticals and Opiant Pharmaceuticals by Amgen and Indivior.
-
Applied UV, Inc. Retains Legal Counsel to Investigate Potential Illegal Naked Short Selling
1/27/2023
Applied UV, Inc. today announced that it has engaged the services of Herrick, Feinstein LLP to investigate potential illegal short selling of the Company’s stock.
-
A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), is requesting that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi (enzalutamide), a prostate cancer therapeutic.
-
BIOLASE REJECTS SONENDO'S PATENTLY ABSURD CLAIMS
1/25/2023
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser company, today released the following statement in response to the attempt by Sonendo, Inc., through its wholly-owned subsidiary PIPStek LLC (Sonendo), to use patent litigation to try to save Sonendo's diminished position and reputation in the marketplace.
-
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
1/23/2023
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond contai
-
Exelixis Announces Update on Patent Litigation with MSN Laboratories
1/19/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to the cabozantinib compound patent (U.S. 7,579,473).
-
The FTC issued a Notice of Proposed Rulemaking (NPRM) that could change the landscape for employer-employee relationships nationwide, specifically in the biopharma industry.
-
American Aires Provides Update on Cease Trade Order
1/16/2023
American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company" or "Aires") announces that, further to its previous press releases of May 9, 2022, June 23, 2022, August 2, 2022, August 26, 2022, September 21, 2022, October 21, 2022, November 3, 2022 and December 6, 2022,
-
Defence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
1/16/2023
Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate
-
ITC Judge Rules Apple Violated U.S. Trade Laws by Infringing Masimo Pulse Oximeter Patent
1/11/2023
A United States Administrative Law Judge in Washington, D.C. ruled that Apple Inc. violated Section 337 of the Tariff Act of 1930 as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of Masimo’s pulse oximeter patents.
-
Settlement reached in Dr. Aysha Khoury's lawsuit against the Kaiser Permanente School of Medicine
1/10/2023
Dr. Aysha Khoury is pleased to announce the settlement of her lawsuit and withdrawal of her National Labor Relations Board charge against the Kaiser Permanente Bernard J. Tyson School of Medicine ("KPSOM").
-
PreveCeutical Signs Intercompany Sol-Gel License Agreement
1/9/2023
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids ("Sol-Gel License").